# 신경 생물표지자 시장

> 신경 바이오마커 시장 조사 보고서 응용 분야별(알츠하이머병, 파킨슨병, 다발성 경화증, 뇌졸중, 간질), 유형별(유전적 바이오마커, 단백질체 바이오마커, 대사체 바이오마커, 이미징 바이오마커), 최종 사용자별(제약 회사, 임상 실험실, 연구 기관, 임상 연구 기관), 기술별(생체 분자 분석, 이미징 기술, 유전체 시퀀싱, 단백질체학) 및 지역별(북미, 유럽, 남미, 아시아-태평양, 중동 및 아프리카) - 2035년까지의 예측.

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.24%
- **2024:** $ 5.04 Billion
- **2025:** $ 5.3 Billion
- **2035:** $ 8.83 Billion
- **Key Players:** Roche (CH), AbbVie(US), Biogen (US), Eli Lilly (US), Novartis (CH), Amgen (US), Merck (DE), Pfizer (US), AstraZeneca (GB)

**Report ID:** MRFR/HC/32076-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** September 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/neurological-biomarker-market-33914

---

## Market Summary

## **Neurological Biomarker Market Overview**

As per MRFR analysis, the Neurological Biomarker Market Size was estimated at 5.04 (USD Billion) in 2024. The Neurological Biomarker Market Industry is expected to grow from 5.30 (USD Billion) in 2025 to 8.39 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.24% during the forecast period (2025 - 2034).

### **Key Neurological Biomarker Market Trends Highlighted**

The Global Neurological Biomarker Market is experiencing significant growth driven by the rising prevalence of neurological disorders and advancements in biomarker discovery technologies. There is an increasing demand for precise diagnostic tools and therapeutic strategies that can lead to early detection and better management of conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Increased awareness about neurological diseases and the importance of biomarkers is helping to propel this market forward. Additionally, the emphasis on personalized medicine is fueling investment in research and development, leading to the advent of novel biomarkers that can improve patient outcomes.

Opportunities in the market arise from the integration of artificial intelligence and machine learning in biomarker research.

These technologies can analyze vast amounts of data, revealing patterns that assist in identifying new biomarkers and enhancing diagnostic accuracy. Furthermore, collaborations among research institutions, diagnostic companies, and pharmaceutical firms can result in innovative solutions that capitalize on the need for effective biomarker-based tools in clinical settings. 

The growing trend of home healthcare and telemedicine also opens new avenues for the deployment of neurological biomarkers in remote patient monitoring.Recent trends indicate a focus on developing biomarkers that can track disease progression and response to therapy, which can provide healthcare professionals with essential information for treatment adjustments. The exploration of neuroimaging techniques and the utilization of blood-based biomarkers are also gaining traction, promising to enhance diagnostic capabilities. The market is witnessing a gradual shift toward non-invasive approaches, reflecting a broader industry trend aimed at improving patient comfort and compliance.

Overall, the Global Neurological Biomarker Market is poised for a transformative phase fueled by innovation, collaboration, and an evolving understanding of neurological diseases.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Neurological Biomarker Market Drivers**

### **Increasing Prevalence of Neurological Disorders**

The Global Neurological Biomarker Market Industry is experiencing substantial growth, primarily driven by the rising incidence of neurological disorders such as [Alzheimer's disease](../../../reports/alzheimers-disease-diagnostic-market-2149), Parkinson's disease, and multiple sclerosis. As the global population ages, the number of individuals affected by these debilitating conditions is on the rise, leading to an increased demand for early diagnosis and effective treatment options. Neurological biomarkers play a crucial role in this context, as they aid in identifying the presence of neural dysfunction at a molecular level.By facilitating early detection, biomarkers enable timely interventions, which can significantly enhance patient outcomes.

Additionally, advancements in genomic and proteomic technologies are unlocking new avenues for research and development in biomarker discovery, further expanding the scope of their application in clinical settings. As healthcare systems worldwide shift towards personalized medicine, the focus on understanding individual patient profiles through biomarkers is expected to grow, thus propelling the market for neurological biomarkers.Consequently, the need for innovative and precise diagnostic tools to manage neurological disorders paves the way for significant investments in the Global Neurological Biomarker Market Industry, ensuring continued advancements in the field.

### **Technological Advancements in Biomarker Discovery**

The Global Neurological Biomarker Market Industry is significantly benefitting from rapid technological advancements in biomarker discovery methodologies. Innovations in fields such as genomics, proteomics, and metabolomics are leading to the development of more sensitive and specific biomarkers. These technologies enable researchers to uncover new biomarkers that can predict disease onset, monitor disease progression, and evaluate treatment responses more effectively.As these advanced tools become integrated into clinical practice, they are expected to drastically improve the accuracy of neurological assessments, driving demand in the biomarker market.

### **Rise in Research and Development Activities**

The Global Neurological Biomarker Market Industry is witnessing a surge in research and development activities, fueled by an increased focus on neurological health. Government and private sector initiatives aimed at funding and supporting research projects related to biomarker identification and validation are playing a pivotal role in this growth. This not only aids in the discovery of new biomarkers for various neurological disorders but also encourages collaboration between academic institutions, biotech companies, and pharmaceutical firms.As research progresses, it is likely to lead to the introduction of novel biomarkers into the market, thereby enhancing diagnostic capabilities and treatment personalization for patients.

## **Neurological Biomarker Market Segment Insights**

### **Neurological Biomarker Market Application Insights**

The Global Neurological Biomarker Market segment focused on Applications has shown considerable growth and importance in the healthcare landscape as of 2023. With a total market revenue of 4.55 USD Billion, the Application segment is further divided into specific conditions such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Stroke, and Epilepsy.

Alzheimer's Disease currently holds a prominent position, valued at 1.5 USD Billion in 2023, and is projected to rise to 2.4 USD Billion by 2032, showcasing a significant demand for innovative diagnostics and therapies in tackling this neurodegenerative disorder. The prominence of this segment is largely attributed to the increasing prevalence of Alzheimer's, which is becoming a major public health concern, reflecting its popularity in the Global Neurological Biomarker Market data.

Similarly, the Parkinson's Disease segment holds a value of 0.9 USD Billion in 2023 and is expected to grow to 1.5 USD Billion by 2032. This growth signifies the escalating research and development efforts aimed at understanding and managing symptoms of Parkinson's, making it a significant area within the Global Neurological Biomarker Market statistics.

Multiple Sclerosis, valued at 0.8 USD Billion in 2023, is another critical segment showing projected growth to 1.2 USD Billion by 2032, emphasizing the need for biomarkers to improve diagnosis and treatment options, as this condition predominantly affects adolescents and young adults.

Meanwhile, Stroke is valued at 0.95 USD Billion in 2023 and is anticipated to reach 1.65 USD Billion by 2032, demonstrating its importance in urgent patient care and the necessity for rapid diagnostic tools.The stroke segment's growth is driven by an increasing number of stroke incidents globally, highlighting the urgent healthcare need it addresses.

Lastly, the Epilepsy segment, currently valued at 0.4 USD Billion and growing to 0.66 USD Billion by 2032, shows a more modest yet notable impact in the market. The significance of neurological biomarkers related to epilepsy lies in the development of personalized medicine approaches, particularly in determining treatment efficacy for patients.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Neurological Biomarker Market Type Insights**

The Global Neurological Biomarker Market is evolving rapidly, with a projected value of 4.55 billion USD in 2023, aimed to reach 7.21 billion USD by 2032. The market segmentation by Type includes Genetic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, and Imaging Biomarkers. Genetic Biomarkers play an essential role in the early detection of various neurological diseases and hold significant potential in personalized medicine. Proteomic Biomarkers are crucial for understanding the pathological processes and identifying potential therapeutic targets, thereby driving the market growth.Metabolomic Biomarkers contribute to insights about disease progression and can aid in monitoring treatment responses.

Imaging Biomarkers are also increasingly significant due to advancements in neuroimaging technologies, allowing for enhanced disease diagnosis and management.

The market growth is supported by rising incidences of neurological disorders, increasing demand for precise diagnostics, and advancements in biomarker discovery techniques. However, challenges such as high developmental costs and stringent regulatory requirements may impact progress.Overall, the diversification in the Global Neurological Biomarker Market segmentation points to a comprehensive landscape with ample opportunities for research and development in the coming years.

### **Neurological Biomarker Market End User Insights**

The Global Neurological Biomarker Market has demonstrated significant potential, with a market valuation of 4.55 billion USD in 2023, reflecting its growing importance across various end-user segments. In this market landscape, Pharmaceutical Companies play a crucial role as they utilize neurological biomarkers to enhance drug development processes for neurological disorders. Clinical Laboratories also significantly contribute, offering essential diagnostic services that leverage these biomarkers for accurate disease identification and management.Research Institutions are pivotal in advancing the Global Neurological Biomarker Market data, conducting studies that lead to innovative biomarker discoveries and applications.

Additionally, Contract Research Organizations (CROs) support the market by providing specialized services that enable efficient and effective clinical trials, essential for new drug approvals. 

As the market expands towards a projected value of 7.21 billion USD by 2032, trends such as increasing investments in neurodegenerative disease research and advancements in biomarker technology are driving growth.However, challenges, including regulatory hurdles and the need for standardization, can impact market dynamics despite the promising opportunities that persist in this evolving industry. Overall, the Global Neurological Biomarker Market segmentation reflects a diverse and robust ecosystem crucial for addressing neurological health challenges.

### **Neurological Biomarker Market Technology Insights**

The Global Neurological Biomarker Market, particularly within the Technology segment, is significantly shaping the diagnostics and treatment landscape. In 2023, the market was valued at 4.55 billion, reflecting a growing recognition of the importance of neurological biomarkers in understanding disorders.

This Technology segment encompasses various crucial aspects such as Biomolecular Analysis, which facilitates the identification of disease markers, and Imaging Techniques that enhance visual interpretations of neurological conditions.

Genomic Sequencing is another critical component underpinning personalized medicine by offering insights into genetic predispositions to neurological diseases.Proteomics plays a significant role as it supports the analysis of protein expressions associated with neurological disorders, providing insights that are critical for developing targeted therapies.

The integration of these technologies not only drives market growth but also enhances the overall understanding of complex neurological conditions, contributing to better patient outcomes. The market, with a projected valuation of 7.21 billion by 2032, indicates a robust expansion driven by innovations and the increasing prevalence of neurological disorders.

### **Neurological Biomarker Market Regional Insights**

The Global Neurological Biomarker Market has shown a diverse array of valuations across its regional segments, with North America leading significantly at a valuation of 2.1 USD Billion in 2023, expected to reach 3.3 USD Billion by 2032. This region dominates largely due to advanced healthcare infrastructure and increased investment in research.

Europe followed with a valuation of 1.2 USD Billion in 2023, projected to grow to 1.9 USD Billion, driven by rising awareness of neurological disorders and the need for innovative diagnostic solutions. The APAC region presents a market value of 0.85 USD Billion in 2023, anticipated to grow to 1.35 USD Billion, reflecting a growing focus on healthcare advancements in emerging economies.South America and MEA have comparatively lower valuations at 0.25 USD Billion and 0.15 USD Billion, respectively, in 2023, with expected increases to 0.4 USD Billion and 0.26 USD Billion by 2032.

However, these regions offer significant growth potential due to increasing healthcare investments and collaborative initiatives for research and development. Overall, regional disparities highlight the importance of tailored market strategies to capitalize on local growth opportunities within the Global Neurological Biomarker Market industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Neurological Biomarker Market Key Players and Competitive Insights**

The Global Neurological Biomarker Market is characterized by a diverse range of players who are leveraging advanced technologies and innovations to deliver next-generation diagnostic solutions. The market comprises numerous companies, both established and emerging, which are collectively focused on enhancing the understanding of neurological conditions through biomarker discovery and validation. Advanced research methodologies combined with sophisticated technology platforms have enabled these companies to foster substantial progress in identifying biomarkers associated with various neurological disorders.Siemens Healthineers stands out in the Global Neurological Biomarker Market with its strong technological infrastructure and commitment to research and development. 

The company has established a significant market presence through its advanced imaging and diagnostic solutions that cater specifically to neurological disorders. With an emphasis on accuracy and reliability, Siemens Healthineers has developed diagnostic technologies that aid in the early detection of conditions such as Alzheimer's disease and other neurodegenerative disorders.

Their dedication to innovation is demonstrated through ongoing partnerships and collaborations with healthcare providers and research institutions, allowing them to stay at the forefront of the evolving landscape in neurological biomarkers.AstraZeneca plays a crucial role within the Global Neurological Biomarker Market by focusing on the development of innovative therapeutics and companion diagnostics for neurological disorders.

The company's robust portfolio is complemented by its significant investment in research initiatives aimed at unlocking the complexities of neurological diseases through biomarker identification. AstraZeneca's collaboration with academic institutions and biotechnology firms enables it to enhance its capabilities in biomarker discovery, facilitating the development of targeted therapies and personalized treatment plans. The company's strengths include a strong emphasis on scientific exploration and a commitment to integrating biomarker research into clinical practice, which supports the drive toward precision medicine.

### **Key Companies in the Neurological Biomarker Market Include**

- [Siemens Healthineers](https://www.siemens-healthineers.com/laboratory-diagnostics/assays-by-diseases-conditions/neurology-assays)
- AstraZeneca
- GSK
- Eli Lilly and Company
- Abbott Laboratories
- Medtronic
- Takeda Pharmaceutical
- Thermo Fisher Scientific
- Merck Group
- Pfizer
- Biogen
- Johnson and  Johnson
- Roche
- Novartis
- Amgen

## Neurological Biomarker Market Industry Developments

- **Q2 2024: Quanterix Launches Simoa® p-Tau 217 Advantage V2 Kit to Advance Alzheimer’s Disease Research** Quanterix announced the launch of its Simoa® p-Tau 217 Advantage V2 Kit, a next-generation neurological biomarker assay designed to improve the detection of Alzheimer’s disease pathology in blood samples.
- **Q2 2024: C2N Diagnostics Announces CE Mark for PrecivityAD2™ Blood Test for Alzheimer’s Disease** C2N Diagnostics received CE Mark approval for its PrecivityAD2™ blood test, enabling its commercial launch in Europe for the detection of Alzheimer’s disease biomarkers.
- **Q2 2024: Alto Neuroscience Raises $45 Million in Series C Financing to Advance Precision Psychiatry Platform** Alto Neuroscience secured $45 million in Series C funding to accelerate the development of its biomarker-driven platform for neurological and psychiatric disorders.
- **Q1 2024: Olink launches new neurology biomarker panel for high-throughput proteomics** Olink introduced a new neurology biomarker panel, expanding its high-throughput proteomics offering to support neurological disease research and drug development.
- **Q1 2024: Neurotrack and Quest Diagnostics Announce Strategic Partnership to Advance Early Detection of Cognitive Decline** Neurotrack and Quest Diagnostics formed a partnership to develop and commercialize digital and blood-based neurological biomarker tests for early detection of cognitive impairment.
- **Q2 2024: Diadem Receives FDA Breakthrough Device Designation for AlzoSure® Predict Blood Test for Alzheimer’s Disease** Diadem announced that its AlzoSure® Predict blood test for early detection of Alzheimer’s disease received Breakthrough Device Designation from the U.S. FDA.
- **Q2 2024: Amprion Receives FDA Breakthrough Device Designation for SYNTap Biomarker Test for Parkinson’s Disease** Amprion’s SYNTap Biomarker Test, designed to detect synucleinopathies such as Parkinson’s disease, was granted Breakthrough Device Designation by the FDA.
- **Q1 2024: Quanterix Appoints Masoud Toloue as Chief Executive Officer** Quanterix announced the appointment of Masoud Toloue as its new CEO, aiming to drive growth in the neurological biomarker sector.
- **Q2 2024: Cerveau Technologies and Eisai Enter Collaboration to Advance Tau PET Imaging Biomarker Research** Cerveau Technologies and Eisai announced a collaboration to advance research and development of tau PET imaging biomarkers for neurodegenerative diseases.
- **Q1 2024: Alzheon Announces $100 Million Series D Financing to Advance ALZ-801 and Biomarker Programs** Alzheon raised $100 million in Series D funding to support late-stage clinical development of ALZ-801 and expansion of its neurological biomarker programs.
- **Q2 2024: NeuroSense Therapeutics Receives FDA Orphan Drug Designation for PrimeC in ALS** NeuroSense Therapeutics received FDA Orphan Drug Designation for PrimeC, a therapy for ALS, which is supported by biomarker-driven clinical development.
- **Q1 2024: Alector and GSK Announce Strategic Collaboration to Develop Novel Neurodegeneration Biomarkers** Alector and GSK entered a strategic collaboration to develop and commercialize novel biomarkers for neurodegenerative diseases.

## **Neurological Biomarker Market Segmentation Insights**

### **Neurological Biomarker Market Application Outlook**

- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Stroke
- Epilepsy

### **Neurological Biomarker Market Type Outlook**

- Genetic Biomarkers
- Proteomic Biomarkers
- Metabolomic Biomarkers
- Imaging Biomarkers

### **Neurological Biomarker Market End User Outlook**

- Pharmaceutical Companies
- Clinical Laboratories
- Research Institutions
- CROs

### **Neurological Biomarker Market Technology Outlook**

- Biomolecular Analysis
- Imaging Techniques
- Genomic Sequencing
- Proteomics

### **Neurological Biomarker Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa ** **

## Market Drivers

### 바이오마커 기술의 발전

신경 바이오마커 시장에서 바이오마커 발견 및 검증의 기술 혁신이 풍경을 변화시키고 있습니다. 고속 스크리닝 방법, 차세대 염기서열 분석 및 고급 이미징 기술의 출현은 신경 바이오마커를 식별하고 특성화하는 능력을 크게 향상시켰습니다. 이러한 발전은 신경 장애의 시기적절한 식별에 필수적인 보다 정확하고 신뢰할 수 있는 진단 도구의 개발을 촉진합니다. 그 결과, 신경 바이오마커 시장은 환자 결과를 개선하고 임상 작업 흐름을 간소화할 수 있는 새로운 바이오마커의 유입을 목격하고 있습니다. 바이오마커 분석에 인공지능 및 기계 학습의 통합은 이 추세를 더욱 강화하여 산업의 유망한 미래를 제시합니다.

### 신경 장애의 증가하는 유병률

신경퇴행성 질환인 알츠하이머병, 파킨슨병, 다발성 경화증의 발생률 증가가 신경 바이오마커 시장의 주요 원인입니다. 최근 추정에 따르면 이러한 질환에 영향을 받는 개인의 수는 크게 증가할 것으로 예상되며, 알츠하이머병만 해도 2050년까지 1,400만 명 이상에 영향을 미칠 것으로 보입니다. 이러한 유병률의 급증은 효과적인 진단 도구와 치료 옵션의 개발을 필요로 하며, 이는 신경 바이오마커에 대한 수요를 촉진하고 있습니다. 의료 시스템이 증가하는 환자 집단을 관리하기 위해 노력함에 따라, 신경 바이오마커 시장은 조기 발견 및 개인 맞춤형 치료 전략의 필요성에 의해 상당한 성장을 경험할 것으로 보입니다.

### 연구 및 개발에 대한 투자 증가

신경 바이오마커 시장은 연구 및 개발 활동에 대한 투자 증가로 혜택을 보고 있습니다. 제약 회사와 연구 기관은 신경 장애의 진단 및 치료에 도움이 될 수 있는 새로운 바이오마커를 탐색하기 위해 자원을 점점 더 많이 할당하고 있습니다. 이러한 추세는 임상 시험 및 바이오마커 검증 연구에 대한 상당한 자금이 지원되고 있다는 사실로 입증됩니다. 2023년에는 신경학 분야의 R&D 지출이 약 300억 달러에 달했다고 보고되었으며, 이는 신경학 연구를 발전시키려는 증가하는 의지를 반영합니다. 이러한 투자는 진단 정확도와 치료 효능을 향상시킬 수 있는 혁신적인 바이오마커를 창출할 가능성이 높으며, 이는 신경 바이오마커 시장의 성장을 촉진할 것입니다.

### 바이오마커 개발을 위한 규제 지원

규제 기관은 바이오마커 개발 및 검증을 지원하는 프레임워크를 제공함으로써 신경 바이오마커 시장의 성장을 촉진하는 중요한 역할을 하고 있습니다. 바이오마커의 승인 프로세스를 신속하게 진행하기 위한 이니셔티브는 제약 회사들이 이 분야에 투자하도록 장려하고 있습니다. 예를 들어, FDA는 약물 개발 및 임상 시험에서 사용하기 위한 바이오마커의 자격을 용이하게 하는 프로그램을 마련했습니다. 이러한 규제 지원은 새로운 바이오마커의 시장 도입을 가속화할 뿐만 아니라 의료 전문가들 사이에서 이러한 도구의 신뢰성을 높입니다. 그 결과, 더 많은 검증된 바이오마커가 임상 사용을 위해 제공됨에 따라 신경 바이오마커 시장은 확장될 가능성이 높습니다.

### 개인화된 의약품에 대한 증가하는 수요

개인화된 의학으로의 전환은 신경 바이오마커 시장에 상당한 영향을 미치고 있습니다. 의료가 일률적인 접근 방식에서 벗어나면서, 개별 환자 프로필에 기반한 치료 맞춤화에 대한 강조가 증가하고 있습니다. 신경 바이오마커는 특정 질병 하위 유형을 식별하고 치료 반응을 예측할 수 있도록 해줌으로써 이러한 패러다임 전환에서 중요한 역할을 합니다. 신경학에서 개인화된 의학 시장은 향후 몇 년 동안 10% 이상의 연평균 성장률로 성장할 것으로 예상됩니다. 이 추세는 표적 치료 개발에서 바이오마커의 중요성을 강조하며, 신경 바이오마커 시장 내 수요를 촉진하고 있습니다.

## Future Outlook

신경 바이오마커 시장은 2024년부터 2035년까지 5.24%의 연평균 성장률(CAGR)로 성장할 것으로 예상되며, 이는 진단 기술의 발전, 신경 장애의 증가하는 유병률, 그리고 증가하는 의료 투자에 의해 촉진될 것입니다.

**New opportunities:**

- 표적 치료를 위한 개인화된 바이오마커 패널 개발.
- 바이오마커 발견 과정에 AI 기반 분석 통합.
- 원격 바이오마커 모니터링을 위한 원격 의료 서비스 확장.

2035년까지 신경 바이오마커 시장은 상당한 성장과 혁신을 반영하며 강력할 것으로 예상됩니다.

## Segment Insights

### 응용 분야별: 알츠하이머병(가장 큰) 대 파킨슨병(가장 빠르게 성장하는)

신경 생체표지자 시장에서 알츠하이머병은 전 세계적으로 질병의 유병률 증가로 인해 가장 큰 점유율을 차지하는 주요 응용 분야로 두드러집니다. 그 뒤를 이어 파킨슨병이 빠르게 성장하는 세그먼트로 자리 잡고 있으며, 이는 인식 증가와 진단 발전에 힘입은 것입니다. 다발성 경화증, 뇌졸중, 간질과 같은 다른 응용 분야도 의미 있는 점유율을 기여하지만 현재 알츠하이머 관련 생체표지자에 대한 상당한 수요에 의해 가려져 있습니다. 신경 생체표지자 시장의 성장 추세는 노인 인구 증가, 생체표지자 발견의 발전, 신경 장애의 조기 진단에 대한 강조 등 여러 요인에 의해 주도되고 있습니다. 연구 및 개발 투자는 특히 알츠하이머병과 파킨슨병에서 매우 중요하며, 지속적인 혁신이 새로운 검사 옵션과 치료법을 촉진하여 삶의 질을 연장하고 체계적인 의료 문제를 해결하는 데 기여하고 있습니다.

알츠하이머병 (우세형) 대 파킨슨병 (신흥)

알츠하이머병은 신경학적 바이오마커 시장의 초석으로, 진단 및 질병 진행 모니터링에 필수적인 다양한 바이오마커를 포함합니다. 이 부문은 상당한 연구 자금 지원과 조기 발견의 필요성에 대한 인식 증가로 혜택을 보고 있습니다. 알츠하이머 바이오마커는 잘 확립되어 있어 임상의에게 신뢰할 수 있는 프레임워크를 제공합니다. 한편, 파킨슨병은 임상 시험과 바이오마커 기술의 혁신에 힘입어 떠오르는 부문을 나타냅니다. 이 부문은 신경 염증과 질병 진행과의 상관관계에 초점을 맞추고 있어 집중적인 연구 및 개발의 영역이 되고 있습니다. 진단 옵션이 더욱 정교해짐에 따라 파킨슨병 바이오마커는 신경퇴행성 연구에서 주목받고 있으며, 확립된 알츠하이머 지표를 보완하고 맞춤형 치료 전략의 긴급한 필요성을 드러내고 있습니다.

### 유형별: 유전적 바이오마커(가장 큼) 대 영상 바이오마커(가장 빠르게 성장함)

신경 바이오마커 시장은 유전적, 단백질적, 대사적 및 이미징 바이오마커를 포함한 다양한 세그먼트 값의 분포를 반영합니다. 이 중 유전적 바이오마커는 신경 장애에 대한 유전적 소인을 식별하는 데 중요한 역할을 하여 가장 큰 시장 점유율을 차지하고 있습니다. 이들은 개인 맞춤형 치료 계획을 개발하는 데 광범위하게 활용됩니다. 현재는 더 작은 세그먼트인 이미징 바이오마커는 기술 발전이 정확성과 신뢰성을 향상시키면서 빠르게 주목받고 있으며, 이는 임상 진단 및 연구에서의 수요 증가로 이어지고 있습니다.

유전적 바이오마커 (우세) 대 영상 바이오마커 (신흥)

유전적 바이오마커는 신경학적 장애에 대한 유전적 소인을 제공하여 조기 진단 및 맞춤형 치료에 도움을 주는 능력 덕분에 신경학적 바이오마커 시장에서 지배적인 힘으로 자리 잡았습니다. 한편, MRI 및 PET 스캔과 같은 최첨단 기술과 비침습적 특성으로 특징지어지는 이미징 바이오마커는 중요한 플레이어로 부상하고 있습니다. 실시간으로 뇌의 변화를 시각화하는 데 대한 집중 증가와 이미징 분석에 인공지능을 통합하는 것이 이들의 빠른 성장을 이끌고 있습니다. 이러한 역학은 신경학적 진단의 지형을 재편하고 있으며, 두 가지 유형 모두 환자 결과 향상에 보완적인 역할을 하고 있습니다.

### 최종 사용자에 의해: 제약 회사(가장 큰) 대 임상 실험실(가장 빠르게 성장하는)

신경 바이오마커 시장은 제약 회사, 임상 실험실, 연구 기관 및 계약 연구 기관(CRO) 등 다양한 최종 사용자로 구성되어 있습니다. 이 중 제약 회사가 가장 큰 시장 점유율을 차지하고 있으며, 바이오마커 개발에 대한 광범위한 자원과 역량을 활용하고 있습니다. 반면, 임상 실험실은 신경 바이오마커를 점점 더 많이 채택하여 진단 서비스를 향상시키고 환자 결과를 개선하는 데 빠르게 주목받고 있습니다. 성장 추세는 제약 회사들이 혁신적인 약물 발견과 개인 맞춤형 의학에 집중하고 있어 신경 바이오마커에 대한 수요를 촉진하고 있음을 나타냅니다. 반면, 임상 실험실은 기술 발전과 신경 장애에 대한 인식 증가로 혜택을 보고 있으며, 이 진화하는 시장에서 주요 플레이어로 자리 잡고 있습니다. 연구 기관과 CRO도 성장에 기여하고 있지만, 주로 협력 및 연구 이니셔티브에 집중하여 더 느린 속도로 진행되고 있습니다.

제약 회사 (지배적) 대 임상 실험실 (신흥)

제약 회사들은 현재 신경 바이오마커 시장에서 지배적인 세력으로 자리 잡고 있으며, 방대한 재정 자원과 연구개발 능력을 활용하여 표적 치료제를 개발하고 있습니다. 그들의 확립된 위치는 임상 시험 및 규제 승인에서 선도할 수 있게 하여 경쟁 우위를 제공합니다. 반면, 임상 실험실은 진단 과정에서의 역할이 점점 더 중요해짐에 따라 중요한 플레이어로 부상하고 있습니다. 기술 발전에 힘입어 이러한 실험실은 신경 질환에 대한 보다 포괄적인 검사를 포함하도록 서비스를 확장하고 있습니다. 개인 맞춤형 의학에 대한 추진력 또한 이러한 변화에 영향을 미치고 있으며, 임상 실험실은 맞춤형 솔루션을 제공하기 위해 적응하고 있습니다. 이 두 부문은 함께 확립된 기업과 신생 기업이 공존하고 번창하는 역동적인 환경을 보여줍니다.

### 기술별: 생체분자 분석(가장 큰) 대 이미징 기술(가장 빠르게 성장하는)

신경 바이오마커 시장은 다양한 기술 발전에 의해 상당한 영향을 받고 있습니다. 생체분자 분석이 이 부문을 선도하며, 주로 확립된 방법론과 신경 장애 진단에 널리 적용되는 덕분에 시장 점유율이 높습니다. 질병 식별 및 모니터링을 위한 다양한 바이오 분자의 활용은 이 부문의 위치를 강화하여 신경 연구 및 임상 응용에서 중요한 부문이 되게 합니다. 이미징 기술은 현재는 작은 점유율을 차지하고 있지만, 고급 MRI 기술 및 기능적 이미징과 같은 혁신으로 빠르게 발전하고 있으며, 이는 신경 질환에 대한 진단 및 치료 계획을 개선할 것을 약속합니다.

생체분자 분석 (주요) 대 이미징 기술 (신흥)

생체분자 분석은 신경 질환의 식별 및 평가를 위해 생물학적 분자를 사용하는 것이 특징입니다. 그 지배력은 잘 확립된 프로토콜과 임상 환경에서의 수용에 기인합니다. 이 분야는 단백질, 효소 및 핵산을 포함한 다양한 기술을 포괄하여 신경 상태에 대한 통찰력을 효과적으로 제공합니다. 반면, 이미징 기술은 MRI 및 PET 스캔과 같은 혁신적인 기술을 자랑하며, 이는 뇌 기능을 이해하고 장애를 식별하는 데 중요한 역할을 하고 있습니다. 아직 발전 중이지만, 정확한 진단에 대한 수요 증가와 더 효율적인 이미징 솔루션을 위한 지속적인 기술 발전 덕분에 빠르게 주목받고 있습니다.

## Regional Market Share Analysis

### North America : Leading Innovation and Research

North America is the largest market for neurological biomarkers, holding approximately 45% of the global share. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a growing prevalence of neurological disorders. Regulatory support from agencies like the FDA accelerates the approval of innovative biomarker tests, driving market growth. The increasing focus on personalized medicine and early diagnosis further fuels demand for these biomarkers. The United States is the primary contributor to this market, with key players such as Roche, AbbVie, and Biogen leading the charge. The competitive landscape is characterized by a mix of established pharmaceutical giants and emerging biotech firms. Canada also plays a significant role, with a growing emphasis on research collaborations and clinical trials, enhancing the overall market dynamics.

### Europe : Regulatory Support and Growth

Europe is the second-largest market for neurological biomarkers, accounting for approximately 30% of the global share. The region's growth is driven by increasing investments in healthcare and a rising incidence of neurological diseases. Regulatory frameworks, such as the European Medicines Agency's guidelines, facilitate the development and approval of innovative biomarkers, enhancing market accessibility. The focus on precision medicine and patient-centric approaches is also a significant growth driver. Leading countries in this region include Germany, France, and the UK, where major pharmaceutical companies like Merck and AstraZeneca are actively involved in biomarker research. The competitive landscape is robust, with numerous collaborations between academia and industry. The presence of well-established healthcare systems and funding for research initiatives further strengthens the market position of neurological biomarkers in Europe.

### Asia-Pacific : Rapidly Growing Market Potential

Asia-Pacific is witnessing rapid growth in the neurological biomarker market, holding approximately 20% of the global share. The region's expansion is fueled by increasing healthcare expenditure, a rising aging population, and a growing awareness of neurological disorders. Countries like China and India are investing heavily in healthcare infrastructure and research, which is expected to drive demand for biomarkers. Regulatory bodies are also becoming more supportive of innovative diagnostic solutions, further catalyzing market growth. China is the largest market in this region, with significant contributions from local biotech firms and multinational corporations. India is emerging as a key player, focusing on research and development in neurological biomarkers. The competitive landscape is evolving, with collaborations between local and international companies enhancing innovation and market reach. The increasing prevalence of neurological diseases in these countries is expected to further boost market dynamics.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the neurological biomarker market, currently holding about 5% of the global share. The growth is driven by increasing healthcare investments and a rising prevalence of neurological disorders. Governments are beginning to recognize the importance of biomarkers in diagnostics, leading to supportive regulatory frameworks. The region's diverse healthcare needs present significant opportunities for market expansion, particularly in countries like South Africa and the UAE. South Africa is the leading market in this region, with a growing focus on research and development in neurological health. The competitive landscape is characterized by a mix of local and international players, with increasing collaborations aimed at enhancing diagnostic capabilities. The presence of key players is still developing, but the potential for growth is substantial as awareness and healthcare access improve across the region.

## Competitive Benchmarking

The Neurological Biomarker Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for early diagnosis and personalized treatment options for neurological disorders. Key players such as Roche (CH), AbbVie (US), and Biogen (US) are strategically positioned to leverage their extensive research capabilities and innovative product pipelines. Roche (CH) focuses on integrating advanced diagnostics with therapeutic solutions, while AbbVie (US) emphasizes partnerships to enhance its biomarker discovery capabilities. Biogen (US), on the other hand, is heavily investing in digital health technologies to improve patient engagement and data collection, thereby shaping a competitive environment that prioritizes innovation and patient-centric approaches.The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly adopting tactics that enhance operational efficiency and reduce time-to-market for new biomarker tests. This competitive structure allows for a diverse range of offerings, although the influence of major players remains significant in setting industry standards and driving technological advancements.
In August Roche (CH) announced a collaboration with a leading AI firm to develop predictive models for Alzheimer’s disease biomarkers. This strategic move is likely to enhance Roche's capabilities in early diagnosis, positioning the company at the forefront of innovation in the neurological biomarker space. The integration of AI into biomarker development could streamline research processes and improve the accuracy of diagnostic tools, thereby reinforcing Roche's competitive edge.
In September AbbVie (US) expanded its partnership with a prominent academic institution to advance research in neurodegenerative diseases. This collaboration is expected to facilitate the discovery of novel biomarkers, which could lead to breakthroughs in treatment options. By aligning with academic leaders, AbbVie is not only enhancing its research portfolio but also fostering an ecosystem of innovation that may yield significant advancements in the field.
In July Biogen (US) launched a new digital platform aimed at enhancing patient monitoring and data collection for neurological disorders. This initiative reflects Biogen's commitment to integrating technology into its operations, potentially improving patient outcomes and engagement. The platform is designed to collect real-time data, which could be invaluable for refining biomarker development and tailoring treatment strategies to individual patient needs.
As of October the competitive trends in the Neurological Biomarker Market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative innovation in addressing complex neurological challenges. Looking ahead, it appears that competitive differentiation will increasingly hinge on technological advancements and the reliability of supply chains, rather than solely on price. This shift suggests a future where innovation and strategic partnerships will be paramount in navigating the evolving landscape of the neurological biomarker market.

## Recent News & Developments

- **Q2 2024: Quanterix Launches Simoa® p-Tau 217 Advantage V2 Kit to Advance Alzheimer’s Disease Research** Quanterix announced the launch of its Simoa® p-Tau 217 Advantage V2 Kit, a next-generation neurological biomarker assay designed to improve the detection of Alzheimer’s disease pathology in blood samples.
- **Q2 2024: C2N Diagnostics Announces CE Mark for PrecivityAD2™ Blood Test for Alzheimer’s Disease** C2N Diagnostics received CE Mark approval for its PrecivityAD2™ blood test, enabling its commercial launch in Europe for the detection of Alzheimer’s disease biomarkers.
- **Q2 2024: Alto Neuroscience Raises $45 Million in Series C Financing to Advance Precision Psychiatry Platform** Alto Neuroscience secured $45 million in Series C funding to accelerate the development of its biomarker-driven platform for neurological and psychiatric disorders.
- **Q1 2024: Olink launches new neurology biomarker panel for high-throughput proteomics** Olink introduced a new neurology biomarker panel, expanding its high-throughput proteomics offering to support neurological disease research and drug development.
- **Q1 2024: Neurotrack and Quest Diagnostics Announce Strategic Partnership to Advance Early Detection of Cognitive Decline** Neurotrack and Quest Diagnostics formed a partnership to develop and commercialize digital and blood-based neurological biomarker tests for early detection of cognitive impairment.
- **Q2 2024: Diadem Receives FDA Breakthrough Device Designation for AlzoSure® Predict Blood Test for Alzheimer’s Disease** Diadem announced that its AlzoSure® Predict blood test for early detection of Alzheimer’s disease received Breakthrough Device Designation from the U.S. FDA.
- **Q2 2024: Amprion Receives FDA Breakthrough Device Designation for SYNTap Biomarker Test for Parkinson’s Disease** Amprion’s SYNTap Biomarker Test, designed to detect synucleinopathies such as Parkinson’s disease, was granted Breakthrough Device Designation by the FDA.
- **Q1 2024: Quanterix Appoints Masoud Toloue as Chief Executive Officer** Quanterix announced the appointment of Masoud Toloue as its new CEO, aiming to drive growth in the neurological biomarker sector.
- **Q2 2024: Cerveau Technologies and Eisai Enter Collaboration to Advance Tau PET Imaging Biomarker Research** Cerveau Technologies and Eisai announced a collaboration to advance research and development of tau PET imaging biomarkers for neurodegenerative diseases.
- **Q1 2024: Alzheon Announces $100 Million Series D Financing to Advance ALZ-801 and Biomarker Programs** Alzheon raised $100 million in Series D funding to support late-stage clinical development of ALZ-801 and expansion of its neurological biomarker programs.
- **Q2 2024: NeuroSense Therapeutics Receives FDA Orphan Drug Designation for PrimeC in ALS** NeuroSense Therapeutics received FDA Orphan Drug Designation for PrimeC, a therapy for ALS, which is supported by biomarker-driven clinical development.
- **Q1 2024: Alector and GSK Announce Strategic Collaboration to Develop Novel Neurodegeneration Biomarkers** Alector and GSK entered a strategic collaboration to develop and commercialize novel biomarkers for neurodegenerative diseases.

## Report Scope

| MARKET SIZE 2024 | 5.036(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 5.3(USD Billion) |
| MARKET SIZE 2035 | 8.833(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.24% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), AbbVie (US), Biogen (US), Eli Lilly (US), Novartis (CH), Amgen (US), Merck (DE), Pfizer (US), AstraZeneca (GB) |
| Segments Covered | Applications, Types, End Users, Technology, Regional |
| Key Market Opportunities | Advancements in precision medicine enhance diagnostic capabilities within the Neurological Biomarker Market. |
| Key Market Dynamics | Rising demand for early diagnosis drives innovation in neurological biomarker development and regulatory adaptations. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: 2035년까지 신경 바이오마커 시장의 예상 시장 가치는 얼마입니까?**
A: 신경 생물표지자 시장은 2035년까지 약 88.33억 USD에 이를 것으로 예상됩니다.

**Q: 2024년 신경 바이오마커 시장의 시장 가치는 얼마였습니까?**
A: 2024년, 신경 생체표지자 시장은 50.36억 USD로 평가되었습니다.

**Q: 2025 - 2035년 예측 기간 동안 신경 생체표지자 시장의 예상 CAGR은 얼마입니까?**
A: 신경 바이오마커 시장의 2025 - 2035년 예측 기간 동안 예상 CAGR은 5.24%입니다.

**Q: 신경 생체표지자 시장에서 주요 기업으로 간주되는 것은 무엇입니까?**
A: 신경 바이오마커 시장의 주요 기업으로는 로슈, 애브비, 바이오젠, 일라이 릴리, 노바티스, 암젠, 머크, 화이자, 그리고 아스트라제네카가 있습니다.

**Q: 2035년까지 신경 바이오마커 시장에서 알츠하이머병의 예상 가치는 얼마입니까?**
A: 알츠하이머병에 대한 신경 생체표지자 시장의 예상 가치는 2035년까지 15억 달러에서 25억 달러로 증가할 것으로 예상됩니다.

**Q: 유전적 바이오마커는 시장 가치 측면에서 단백질체 바이오마커와 어떻게 비교됩니까?**
A: 유전적 바이오마커는 15억 9백만 달러에서 26억 4천 6백만 달러로 성장할 것으로 예상되며, 단백질체 바이오마커는 10억 7백만 달러에서 17억 4천 9백만 달러로 증가할 것으로 보입니다. 2035년까지.

**Q: 2035년까지 신경 바이오마커 시장에서 임상 실험실의 예상 시장 규모는 얼마입니까?**
A: 임상 실험실의 시장 규모는 2035년까지 10.08억 USD에서 17.5억 USD로 성장할 것으로 예상됩니다.

**Q: 신경 바이오마커 시장에 영향을 미칠 것으로 예상되는 기술 발전은 무엇입니까?**
A: 생체분자 분석, 이미징 기술, 유전체 시퀀싱 및 단백질체학의 기술 발전은 시장 성장을 촉진할 것으로 예상되며, 2035년까지 평가액이 상당히 증가할 것으로 예상됩니다.

**Q: 2035년까지 뇌졸중 관련 바이오마커의 예상 시장 규모는 얼마입니까?**
A: 뇌졸중 관련 바이오마커의 시장 규모는 2035년까지 9억 달러에서 15억 달러로 증가할 것으로 예상됩니다.

**Q: 신경 생물표지자 시장의 성장은 다양한 응용 분야에서 어떻게 비교됩니까?**
A: 신경 바이오마커 시장은 응용 분야에 따라 다양한 성장을 보이며, 알츠하이머병과 파킨슨병이 2035년까지 가장 높은 가치를 경험할 것으로 예상됩니다.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/neurological-biomarker-market-33914*